Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 217.84 Billion KRW | 4.86% |
| 2022 | 207.74 Billion KRW | -8.14% |
| 2021 | 226.15 Billion KRW | 35.54% |
| 2020 | 166.85 Billion KRW | 0.56% |
| 2019 | 165.92 Billion KRW | 27.24% |
| 2018 | 130.4 Billion KRW | 0.0% |
| 2017 | 130.4 Billion KRW | 0.0% |
| 2016 | 130.4 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 218.87 Billion KRW | 0.47% |
| 2024 Q2 | 226.33 Billion KRW | -0.86% |
| 2023 Q4 | 217.84 Billion KRW | 499.98% |
| 2023 FY | 217.84 Billion KRW | 4.86% |
| 2023 Q2 | 222.05 Billion KRW | 6.39% |
| 2023 Q1 | 208.71 Billion KRW | 0.47% |
| 2023 Q3 | 36.3 Billion KRW | -83.65% |
| 2022 Q1 | 190.15 Billion KRW | -15.92% |
| 2022 Q4 | 207.74 Billion KRW | 7.11% |
| 2022 Q3 | 193.95 Billion KRW | 1.57% |
| 2022 Q2 | 190.96 Billion KRW | 0.43% |
| 2022 FY | 207.74 Billion KRW | -8.14% |
| 2021 Q2 | 223.19 Billion KRW | -3.93% |
| 2021 Q3 | 224.62 Billion KRW | 0.64% |
| 2021 Q4 | 226.15 Billion KRW | 0.68% |
| 2021 FY | 226.15 Billion KRW | 35.54% |
| 2021 Q1 | 232.31 Billion KRW | 39.23% |
| 2020 Q1 | 167.98 Billion KRW | 1.24% |
| 2020 Q2 | 167.71 Billion KRW | -0.16% |
| 2020 FY | 166.85 Billion KRW | 0.56% |
| 2020 Q4 | 166.85 Billion KRW | -0.21% |
| 2020 Q3 | 167.2 Billion KRW | -0.31% |
| 2019 Q4 | 165.92 Billion KRW | -0.52% |
| 2019 Q3 | 166.78 Billion KRW | 0.03% |
| 2019 Q2 | 166.73 Billion KRW | 0.01% |
| 2019 Q1 | 166.72 Billion KRW | 27.85% |
| 2019 FY | 165.92 Billion KRW | 27.24% |
| 2018 Q2 | 135.41 Billion KRW | 3.85% |
| 2018 Q4 | 130.4 Billion KRW | 0.0% |
| 2018 Q1 | 130.4 Billion KRW | 0.0% |
| 2018 Q3 | 130.4 Billion KRW | -3.71% |
| 2018 FY | 130.4 Billion KRW | 0.0% |
| 2017 Q3 | 130.4 Billion KRW | 0.0% |
| 2017 Q1 | 130.4 Billion KRW | 0.0% |
| 2017 FY | 130.4 Billion KRW | 0.0% |
| 2017 Q2 | 130.4 Billion KRW | 0.0% |
| 2017 Q4 | 130.4 Billion KRW | 0.0% |
| 2016 FY | 130.4 Billion KRW | 0.0% |
| 2016 Q4 | 130.4 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -351.434% |
| Yuhan Corporation | 230.07 Billion KRW | 5.316% |
| Yuhan Corporation | 230.07 Billion KRW | 5.316% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -452.796% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -452.796% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -452.796% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 42.983% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -23.858% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 68.515% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -27.931% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -27.931% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -27.931% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -36482.091% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 53.456% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -403.413% |
| HANDOK Inc. | 300.01 Billion KRW | 27.389% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -25.898% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -610.458% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -174.404% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -20.356% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -91381.46% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -49.155% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -225.709% |
| Boryung Corporation | 204.21 Billion KRW | -6.672% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -455.648% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -83.618% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -155.803% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -155.803% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 53.438% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 7.554% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -16779.979% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -34367.143% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -140.756% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -372.014% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -372.014% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -440.026% |
| CKD Bio Corp. | 146.92 Billion KRW | -48.265% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 53.62% |
| JW Holdings Corporation | 554.58 Billion KRW | 60.72% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 3.205% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 61.974% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 46.438% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 0.875% |
| JW Lifescience Corporation | 46.31 Billion KRW | -370.369% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -156.387% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -721.018% |